Anti-programmed death-1 immunotherapy-promising treatment for metastatic colorectal cancer: A case report

Table 1 Timeline of treatments received by the patient and the subsequent outcome

Time period	Treatment and dose	Results
From September 28, 2018 to December 11, 2018	Bevacizumab + FOLFOX treatment (bevacizumab 300 mg day 1 + oxaliplatin 150 mg day 1 + calcium folinate 200 mg day 1 + fluorouracil 0.5 g day 1, fluorouracil 2.0 g civ 46 hours)	Stable disease
From December 25, 2018 to January 26, 2019	FOLFOX treatment (oxaliplatin 150 mg day 1 + calcium folinate 200 mg day 1 + fluorouracil 0.5 g day 1, fluorouracil 2.0 g civ 46 hour)	Progressive disease
February 18, 2019	RFA	Progressive disease
February 23, 2019	Bevacizumab 300mg day 1 + oxaliplatin 150 mg day 1 + raltitrexed 5 mg day 1	Progressive disease
From March 9, 2019 to May 11, 2019	Bevacizumab + FOLFIRI treatment (bevacizumab 300 mg day 1 + irinotecan 200 mg day 1 + calcium folinate 200 mg day 1 + fluorouracil 0.5 g day 1, fluorouracil 2.0 g civ 46 hours)	Progressive disease
From June 29, 2019 to September 19, 2019	Irinotecan 200 mg day 1 + capecitabine 1.5 g day 1-day 14	Progressive disease
From October 2019 to October 2021	Anti-PD-1 immunotherapy (toripalimab 240 mg day 1)	Stable disease
From October 2021 to September 2024	Single Traditional Chinese Medicine treatment	Stable disease

Civ: Continuous intravenous infusion; RFA: Radiofrequency ablation; PD-1: Programmed death-1.